or Try an Advanced Search...

    Technical Analysis for COGT - Cogent Biosciences, Inc.

    Grade Last Price % Change Price Change
    B 8.94 6.05% 0.51
    COGT closed up 6.05 percent on Monday, July 1, 2024, on 68 percent of normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical COGT trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    20 DMA Resistance Bearish 6.05%
    Bollinger Band Squeeze Range Contraction 6.05%
    BB Squeeze Started Range Contraction 6.05%
    20 DMA Resistance Bearish 5.92%
    Outside Day Range Expansion 5.92%
    NR7 Range Contraction 10.37%
    Fell Below 20 DMA Bearish 7.45%
    Older End-of-Day Signals for COGT ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 9 hours ago
    Up 1 ATR about 9 hours ago
    Rose Above Previous Day's High about 10 hours ago
    Rose Above Upper Bollinger Band about 10 hours ago
    Up 5% about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    COGT Chart by TradingView
    Basic chart:

    Profile

    Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors

    Is COGT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
    Jun 23 Cogent Biosciences: Inflection Year Directly Ahead
    Jun 14 Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
    May 24 Cogent Bio spikes after updating late-stage data for lead asset
    May 23 Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
    May 23 Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
    May 13 We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
    May 7 Cogent Biosciences EPS of -$0.62 misses by $0.11
    May 7 Cogent Biosciences Reports First Quarter 2024 Financial Results
    Apr 9 Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
    See more COGT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.36
    52 Week Low 3.67
    Average Volume 1,400,520
    200-Day Moving Average 7.35
    50-Day Moving Average 7.87
    20-Day Moving Average 8.62
    10-Day Moving Average 8.56
    Average True Range 0.63
    RSI (14) 57.45
    ADX 10.77
    +DI 22.00
    -DI 19.23
    Chandelier Exit (Long, 3 ATRs) 7.39
    Chandelier Exit (Short, 3 ATRs) 8.84
    Upper Bollinger Bands 9.15
    Lower Bollinger Band 8.09
    Percent B (%b) 0.8
    BandWidth 12.32
    MACD Line 0.18
    MACD Signal Line 0.23
    MACD Histogram -0.0496
    Fundamentals Value
    Market Cap 769.95 Million
    Num Shares 86.1 Million
    EPS -2.34
    Price-to-Earnings (P/E) Ratio -3.82
    Price-to-Sales 1320.63
    Price-to-Book 3.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.01
    Resistance 3 (R3) 9.93 9.51 9.83
    Resistance 2 (R2) 9.51 9.24 9.54 9.77
    Resistance 1 (R1) 9.22 9.07 9.37 9.30 9.71
    Pivot Point 8.80 8.80 8.87 8.83 8.80
    Support 1 (S1) 8.51 8.53 8.66 8.59 8.17
    Support 2 (S2) 8.09 8.36 8.12 8.11
    Support 3 (S3) 7.80 8.09 8.05
    Support 4 (S4) 7.88